The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, hiv-seronegative volunteers

AIDS

Volumn 24, Issue 2, 2010, Pages 265-270

  Pao, Vivian Y ^a,b   Lee, Grace A ^a,b   Taylor, Steven ^a,b   Aweeka, Francesca T ^c   Schwarz, Jean Marc ^a,d,e   Mulligan, Kathleen ^a,d   Schambelan, Morris ^a,d   Grunfeld, Carl ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

^e Touro University California   (United States)

Author keywords

HIV; HIV protease inhibitors; Insulin resistance; Ritonavir; Triglycerides

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOPINAVIR PLUS RITONAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; GLUCOSE CLAMP TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; CHOLESTEROL; DRUG COMBINATIONS; GLUCOSE CLAMP TECHNIQUE; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HUMANS; INSULIN; LIPID METABOLISM; LIPOPROTEINS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; TRIGLYCERIDES;

EID: 74249095981     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328333af1c     Document Type: Article

References (19)

1. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184. (Pubitemid 40720744)
2. Dube MP, Edmondson-Melancon H, Qian D, Aqeel R, Johnson D, Buchanan TA. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and b-cell function in HIV-infected patients. J Acquir Immune Defic Syndr 2001; 27:130-134.
3. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-F18.
4. LeeGA, RaoMN, MulliganK, LoJC, AweekaF, SchwarzJM, et al. The effects of ritonavir and amprenavir on insulin-mediated glucose disposal in healthy volunteers: two randomized, placebo-controlled, cross-over trials. AIDS 2007; 21:2183-2190.
5. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16:F1-F8.
6. Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137-2144.
7. Dube MP, Qian D, Edmondson-Melancon H, Sattler FR, Goodwin D, Martinez C, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002; 35:475-481.
8. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58:773-795.
9. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004; 88:787-835; ix.
10. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
11. Lee G, Lo J, Aweeka F, Schwarz J, Mulligan K, Schambelan M, Grunfeld C. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006; 43:658-660.
12. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18:641-649.
13. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003; 52:918-925.
14. Schwarz J, Neese R, Turner S, Dare D, Hellerstein M. Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipo-genesis, lipolysis, and whole-body fuel selection. J Clin Invest 1995; 96:2735-2743.
15. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-E223.
16. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419. (Pubitemid 15018832)
17. Lohman TG, Roche AF, Martoll R, editors. Anthropometric standardization reference manual, abridged edition. Champaign, IL: Human Kinetics Books; 1988.
18. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813-1821.
19. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996; 39:298-305.